Autonomix Medical, Inc. Granted U.S. Patent on Platform Technology Enabling Precision Nerve-Targeted Therapies in Cardiology

With over 120 issued and pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sensing and modulation Newly issued patent strengthens the Company’s strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other high-burden diseases THE WOODLANDS, TX, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing ...